These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 33202410)

  • 1. Serum Copeptin, NLPR3, and suPAR Levels among Patients with Autosomal-Dominant Polycystic Kidney Disease with and without Impaired Renal Function.
    Raptis V; Loutradis C; Boutou AK; Faitatzidou D; Sioulis A; Ferro CJ; Papagianni A; Sarafidis PA
    Cardiorenal Med; 2020; 10(6):440-451. PubMed ID: 33202410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levels of Endocan, Angiopoietin-2, and Hypoxia-Inducible Factor-1a in Patients with Autosomal Dominant Polycystic Kidney Disease and Different Levels of Renal Function.
    Raptis V; Bakogiannis C; Loutradis C; Boutou AK; Lampropoulou I; Intzevidou E; Sioulis A; Balaskas E; Sarafidis PA
    Am J Nephrol; 2018; 47(4):231-238. PubMed ID: 29597186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum Fas Ligand, Serum Myostatin and Urine TGF-β1 Are Elevated in Autosomal Dominant Polycystic Kidney Disease Patients with Impaired and Preserved Renal Function.
    Raptis V; Bakogiannis C; Loutradis C; Boutou AK; Sioulis A; Balaskas E; Zebekakis P; Sarafidis PA
    Kidney Blood Press Res; 2018; 43(3):744-754. PubMed ID: 29794429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble Urokinase Plasminogen Activator Receptor and Decline in Kidney Function in Autosomal Dominant Polycystic Kidney Disease.
    Hayek SS; Landsittel DP; Wei C; Zeier M; Yu ASL; Torres VE; Roth S; Pao CS; Reiser J
    J Am Soc Nephrol; 2019 Jul; 30(7):1305-1313. PubMed ID: 31171572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD).
    Nakajima A; Lu Y; Kawano H; Horie S; Muto S
    Clin Exp Nephrol; 2015 Dec; 19(6):1199-205. PubMed ID: 25715868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Copeptin levels and kidney function in ADPKD: case-control study.
    Corradi V; Martino F; Gastaldon F; Scalzotto E; Caprara C; Fortunato A; Pinaffo G; Marchetti C; Fabbi F; Giavarina D; Ferrari F; Rosner MH; Ronco C
    Clin Nephrol; 2016 Sep; 86(9):147-53. PubMed ID: 27487355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kidney function and plasma copeptin levels in healthy kidney donors and autosomal dominant polycystic kidney disease patients.
    Zittema D; van den Berg E; Meijer E; Boertien WE; Muller Kobold AC; Franssen CF; de Jong PE; Bakker SJ; Navis G; Gansevoort RT
    Clin J Am Soc Nephrol; 2014 Sep; 9(9):1553-62. PubMed ID: 24993447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated asymmetric dimethylarginine is associated with oxidant stress aggravation in patients with early stage autosomal dominant polycystic kidney disease.
    Raptis V; Georgianos PI; Sarafidis PA; Sioulis A; Makedou K; Makedou A; Grekas DM; Kapoulas S
    Kidney Blood Press Res; 2013; 38(1):72-82. PubMed ID: 24577239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment.
    Zittema D; Boertien WE; van Beek AP; Dullaart RP; Franssen CF; de Jong PE; Meijer E; Gansevoort RT
    Clin J Am Soc Nephrol; 2012 Jun; 7(6):906-13. PubMed ID: 22516290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apelin and copeptin: two opposite biomarkers associated with kidney function decline and cyst growth in autosomal dominant polycystic kidney disease.
    Lacquaniti A; Chirico V; Lupica R; Buemi A; Loddo S; Caccamo C; Salis P; Bertani T; Buemi M
    Peptides; 2013 Nov; 49():1-8. PubMed ID: 23973863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease.
    Boertien WE; Meijer E; Zittema D; van Dijk MA; Rabelink TJ; Breuning MH; Struck J; Bakker SJ; Peters DJ; de Jong PE; Gansevoort RT
    Nephrol Dial Transplant; 2012 Nov; 27(11):4131-7. PubMed ID: 22523115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort.
    Boertien WE; Meijer E; Li J; Bost JE; Struck J; Flessner MF; Gansevoort RT; Torres VE;
    Am J Kidney Dis; 2013 Mar; 61(3):420-9. PubMed ID: 23089511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.
    Gansevoort RT; van Gastel MDA; Chapman AB; Blais JD; Czerwiec FS; Higashihara E; Lee J; Ouyang J; Perrone RD; Stade K; Torres VE; Devuyst O;
    Kidney Int; 2019 Jul; 96(1):159-169. PubMed ID: 30898339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
    Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelial dysfunction and oxidative stress in polycystic kidney disease.
    Klawitter J; Reed-Gitomer BY; McFann K; Pennington A; Klawitter J; Abebe KZ; Klepacki J; Cadnapaphornchai MA; Brosnahan G; Chonchol M; Christians U; Schrier RW
    Am J Physiol Renal Physiol; 2014 Dec; 307(11):F1198-206. PubMed ID: 25234311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-Inheritance of Autosomal Dominant Polycystic Kidney Disease and Naevoid Basal Cell Carcinoma Syndrome: Effects on Renal Progression.
    Martínez MF; Mazzuoccolo LD; Oddo EM; Iscoff PV; Muchnik C; Neumann HPH; Martin RS; Fraga AR; Azurmendi PJ
    Nephron; 2018; 140(4):282-288. PubMed ID: 30368514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral augmentation index and vascular inflammation in autosomal dominant polycystic kidney disease.
    Heffernan KS; Kuvin JT; Sarnak MJ; Perrone RD; Miskulin DC; Rudym D; Chandra P; Karas RH; Menon V
    Nephrol Dial Transplant; 2011 Aug; 26(8):2515-21. PubMed ID: 21292815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease.
    Meijer E; Bakker SJ; van der Jagt EJ; Navis G; de Jong PE; Struck J; Gansevoort RT
    Clin J Am Soc Nephrol; 2011 Feb; 6(2):361-8. PubMed ID: 20930090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exercise capacity in polycystic kidney disease.
    Reinecke NL; Cunha TM; Heilberg IP; Higa EM; Nishiura JL; Neder JA; Almeida WS; Schor N
    Am J Kidney Dis; 2014 Aug; 64(2):239-46. PubMed ID: 24787761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endothelial Dysfunction and Atherosclerosis in Patients With Autosomal Dominant Polycystic Kidney Disease.
    Ekinci İ; Buyukkaba M; Cinar A; Tunc M; Cebeci E; Gursu M; Kazancioglu R
    Cureus; 2021 Feb; 13(2):e13561. PubMed ID: 33815976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.